Chemotherapy-Induced, Broadly Reactive Autoantibodies in a Colon Cancer Patient

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• The relationship between cancer and autoimmunity is established, with autoantibodies common in cancer patients and autoimmune diseases increasing cancer risk.
• The impact of chemotherapy on inducing autoimmune reactions is not well understood.

Observation:

• This study monitored immunoglobulin M (IgM) responses to human tissues and tumors during chemotherapy in a patient with metastatic colon cancer.
• The patient received seven cycles of the FOLFIRI regimen (folinic acid/fluorouracil/irinotecan) plus cetuximab.

Findings:

• IgM levels against various tissues rose after the first chemotherapy cycle and peaked by the third cycle.
• While autoimmune responses decreased during later cycles, they remained elevated above baseline for most tissues.
• Chemotherapy appears to induce broadly reactive autoimmune responses.

Implications:

• Chemotherapy can initiate widespread autoimmune reactions.
• Monitoring self-reactive IgM during cancer treatment could help mitigate autoimmunity-related adverse events.
• Further research is needed to explore the clinical significance of chemotherapy-induced autoimmunity.